Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Update

Bionano Genomics, Inc. (NASDAQ:BNGO) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 17,650,000 shares, a growth of 11.4% from the December 15th total of 15,840,000 shares. Approximately 12.7% of the company’s stock are sold short. Based on an average daily volume of 6,670,000 shares, the days-to-cover ratio is presently 2.6 days.

Analyst Ratings Changes

Separately, LADENBURG THALM/SH SH lowered shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Friday, November 15th.

Bionano Genomics Stock Performance

Shares of NASDAQ:BNGO traded down $0.01 during trading on Friday, reaching $0.19. The company had a trading volume of 7,196,647 shares, compared to its average volume of 13,889,912. Bionano Genomics has a fifty-two week low of $0.18 and a fifty-two week high of $1.40. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.99. The stock’s fifty day moving average price is $0.24 and its 200 day moving average price is $0.38. The firm has a market capitalization of $22.61 million, a price-to-earnings ratio of -0.08 and a beta of 2.22.

Hedge Funds Weigh In On Bionano Genomics

Several institutional investors have recently bought and sold shares of the company. Carret Asset Management LLC boosted its stake in shares of Bionano Genomics by 89.0% in the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after buying an additional 40,055 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Bionano Genomics in the third quarter valued at about $46,000. Geode Capital Management LLC boosted its holdings in Bionano Genomics by 47.3% during the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after buying an additional 283,639 shares in the last quarter. Finally, Armistice Capital LLC purchased a new position in Bionano Genomics in the second quarter valued at about $1,138,000. 11.35% of the stock is owned by institutional investors and hedge funds.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.